Management of Sleep Disturbances in Alzheimer's Disease

Non-Pharmacological Interventions

The American Academy of Family Physicians recommends establishing a predictable daily routine with consistent wake times, meal times, and bedtime to reinforce circadian rhythms in elderly patients with Alzheimer's disease 1, 3
Optimizing light exposure by maximizing bright light exposure during morning hours and reducing evening light exposure can reduce confusion and restlessness at night, as suggested by the American Family Physician 1, 3
Implementing structured physical exercise programs, including both aerobic activities and anaerobic exercise, can reduce neuropsychiatric symptoms and improve physical function in mild to severe Alzheimer's disease, according to BioScience Trends 2, 3
Reducing evening stimulation by avoiding crowded places, excessive noise from television, and household clutter can lead to agitation and disorientation, as noted by the American Family Physician 1, 3
Using orientation aids, including calendars, clocks, and color-coded labels, can help with time orientation, as recommended by the American Family Physician 1, 3

The American College of Physicians suggests that cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are recommended as first-line pharmacological treatment for mild to moderate Alzheimer's disease, which may indirectly affect sleep-wake cycles 2, 4, 3
Donepezil can be started at 5 mg once daily, may increase to 10 mg daily after 4-6 weeks, and has demonstrated a 1-3 point improvement on the ADAS-cog scale, as reported by the Annals of Internal Medicine 2, 1, 4
Rivastigmine can be initiated at 1.5 mg twice daily, increased by 1.5 mg twice daily every 4 weeks as tolerated, with a maximum dose of 6 mg twice daily, according to BioScience Trends 2, 1
Galantamine can be started at 4 mg twice daily with meals, increased to 8 mg twice daily after 4 weeks, and may be increased to 12 mg twice daily based on tolerability, as suggested by BioScience Trends 2, 1
Memantine, alone or in combination with a cholinesterase inhibitor, is recommended for moderate to severe disease, providing cumulative, additive benefits over monotherapy, as noted by the Journal of Internal Medicine 2, 4, 5

The American Family Physician recommends identifying and addressing environmental triggers and ensuring all comorbid medical conditions are optimally treated when sleep disturbances persist despite non-pharmacological interventions 1, 3
Avoiding medications with anticholinergic side effects that can worsen cognitive symptoms and potentially disrupt sleep-wake cycles is suggested by Praxis Medical Insights 3
Considering cholinesterase inhibitors may reduce behavioral disturbances, including sleep problems, as noted by the American Family Physician 1, 3

Sleep disturbances typically worsen as Alzheimer's disease progresses, requiring ongoing reassessment and treatment adjustment, as reported by the American Family Physician 1
Avoid relying solely on pharmacological approaches without implementing environmental and behavioral strategies, as non-pharmacological interventions have demonstrated efficacy with minimal risk, according to Praxis Medical Insights 3
All symptomatic therapies for Alzheimer's disease do not alter the underlying disease process, and patients continue to experience decline over time despite treatment, as noted by the Journal of Internal Medicine 5
Registering patients at risk for wandering, which may occur during nighttime confusion, in the Alzheimer's Association Safe Return Program is recommended by the American Family Physician 1, 3